Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.410
0.00 (0.00%)
At close: Nov 20, 2024, 4:00 PM
2.400
-0.010 (-0.41%)
Pre-market: Nov 21, 2024, 6:11 AM EST
Esperion Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 295.45 | 116.33 | 75.48 | 78.45 | 227.55 | 148.36 | Upgrade
|
| Revenue Growth (YoY) | 187.12% | 54.14% | -3.79% | -65.52% | 53.37% | - | Upgrade
|
| Cost of Revenue | 107.43 | 129.37 | 145.89 | 120.19 | 149.33 | 175.61 | Upgrade
|
| Gross Profit | 188.03 | -13.04 | -70.42 | -41.75 | 78.22 | -27.25 | Upgrade
|
| Selling, General & Admin | 171.57 | 142.52 | 109.08 | 171.74 | 199.62 | 65.85 | Upgrade
|
| Operating Expenses | 171.57 | 142.52 | 109.08 | 171.74 | 199.62 | 65.85 | Upgrade
|
| Operating Income | 16.46 | -155.56 | -179.5 | -213.48 | -121.4 | -93.1 | Upgrade
|
| Interest Expense | -57.89 | -58.98 | -56.81 | -46.35 | -22.67 | -8.12 | Upgrade
|
| Interest & Investment Income | 7.3 | 4.4 | 2.4 | 0.1 | 0.5 | 3.7 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.6 | 0.48 | 0.53 | 1.24 | -0.08 | 0.06 | Upgrade
|
| EBT Excluding Unusual Items | -33.54 | -209.66 | -233.38 | -258.49 | -143.65 | -97.47 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.41 | -0.28 | -0.01 | 0.1 | 0.3 | Upgrade
|
| Legal Settlements | - | - | - | -18.25 | - | - | Upgrade
|
| Other Unusual Items | -53.24 | - | - | 2.65 | - | - | Upgrade
|
| Pretax Income | -86.77 | -209.25 | -233.66 | -269.11 | -143.55 | -97.17 | Upgrade
|
| Net Income | -86.77 | -209.25 | -233.66 | -269.11 | -143.55 | -97.17 | Upgrade
|
| Net Income to Common | -86.77 | -209.25 | -233.66 | -269.11 | -143.55 | -97.17 | Upgrade
|
| Shares Outstanding (Basic) | 166 | 103 | 66 | 29 | 27 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 166 | 103 | 66 | 29 | 27 | 27 | Upgrade
|
| Shares Change (YoY) | 78.21% | 55.26% | 129.76% | 5.20% | 1.42% | 1.26% | Upgrade
|
| EPS (Basic) | -0.52 | -2.03 | -3.52 | -9.31 | -5.22 | -3.59 | Upgrade
|
| EPS (Diluted) | -0.52 | -2.03 | -3.52 | -9.31 | -5.22 | -3.59 | Upgrade
|
| Free Cash Flow | -26.08 | -135.49 | -174.83 | -263.81 | -86.05 | -71.29 | Upgrade
|
| Free Cash Flow Per Share | -0.16 | -1.31 | -2.63 | -9.13 | -3.13 | -2.63 | Upgrade
|
| Gross Margin | 63.64% | -11.21% | -93.30% | -53.21% | 34.37% | -18.36% | Upgrade
|
| Operating Margin | 5.57% | -133.72% | -237.83% | -272.13% | -53.35% | -62.75% | Upgrade
|
| Profit Margin | -29.37% | -179.87% | -309.58% | -343.04% | -63.09% | -65.49% | Upgrade
|
| Free Cash Flow Margin | -8.83% | -116.46% | -231.64% | -336.29% | -37.81% | -48.05% | Upgrade
|
| EBITDA | 16.5 | -155.4 | -179 | -212.87 | -120.85 | -92.78 | Upgrade
|
| EBITDA Margin | 5.58% | -133.58% | -237.17% | -271.35% | -53.11% | -62.54% | Upgrade
|
| D&A For EBITDA | 0.04 | 0.16 | 0.5 | 0.61 | 0.55 | 0.32 | Upgrade
|
| EBIT | 16.46 | -155.56 | -179.5 | -213.48 | -121.4 | -93.1 | Upgrade
|
| EBIT Margin | 5.57% | -133.72% | -237.83% | -272.13% | -53.35% | -62.75% | Upgrade
|
| Revenue as Reported | 295.45 | 116.33 | 75.48 | 78.45 | 227.55 | 148.36 | Upgrade
|
| Advertising Expenses | - | 15.6 | 11.3 | 13.7 | 19.3 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.